NASDAQ:NTGN

Neon Therapeutics (NTGN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$3.07
$3.07
50-Day Range
$2.77
$3.07
52-Week Range
$0.88
$6.25
Volume
N/A
Average Volume
516,108 shs
Market Capitalization
$88.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NTGN stock logo

About Neon Therapeutics Stock (NASDAQ:NTGN)

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

NTGN Stock News Headlines

BCYC Bicycle Therapeutics plc
NTGN_old Historical Data
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
NBCO Neon Bloom, Inc.
See More Headlines
Receive NTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/02/2020
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:NTGN
CIK
N/A
Fax
N/A
Employees
102
Year Founded
N/A

Profitability

Net Income
$-79,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.50 per share

Miscellaneous

Free Float
N/A
Market Cap
$88.93 million
Optionable
Not Optionable
Beta
-0.81
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Hugh O'Dowd (Age 54)
    Pres, CEO & Director
  • Dr. Eric S. Lander (Age 62)
    Founder & Director
  • Dr. Yasir B. Al-Wakeel (Age 37)
    Chief Financial Officer
  • Dr. Richard Gaynor (Age 69)
    Pres of R&D
  • Dr. Edward Fritsch Ph.D.
    Founder and Chief Technology Officer

NTGN Stock Analysis - Frequently Asked Questions

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) posted its earnings results on Monday, March, 2nd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03.

What other stocks do shareholders of Neon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include VBI Vaccines (VBIV), Aduro Biotech (ADRO), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Pfizer (PFE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), T2 Biosystems (TTOO) and Vaxart (VXRT).

When did Neon Therapeutics IPO?

Neon Therapeutics (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager.

This page (NASDAQ:NTGN) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners